Page last updated: 2024-12-10

ceramide 1-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ceramide 1-phosphate : A phosphosphingolipid consisting of any ceramide phosphorylated at position 1 [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N-octadecanoylsphingosine 1-phosphate : A ceramide 1-phosphate that is the N-octadecananoyl (stearoyl) derivative of sphingosine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283583
CHEBI ID73144
MeSH IDM0180276

Synonyms (20)

Synonym
n-octadecanoylsphing-4-enine 1-phosphate
ceramide 1-phosphate
ceramide 1-phosphate from bovine brain, ~95%
LMSP02050004 ,
n-(octadecanoyl)-sphing-4-enine-1-phosphate
c18 cerp
cerp(d18:1/18:0)
[(e,2s,3r)-3-hydroxy-2-(octadecanoylamino)octadec-4-enyl] dihydrogen phosphate
CHEBI:73144
n-stearoylsphing-4-enine 1-phosphate
n-stearoylsphingosine 1-phosphate
n-octadecanoylsphingosine 1-phosphate
(2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl dihydrogen phosphate
128543-23-7
DTXSID90415280
Q27140345
202063-34-1
(2s,3r,e)-3-hydroxy-2-stearamidooctadec-4-en-1-yl dihydrogen phosphate
PD124531
cerp 18:1;2o/18:0
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acylsphingosine 1-phosphateA ceramide phosphate compound having the phosphate group in the 1-position and an unspecified acyl group atached to the nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Sphingolipid Metabolism2335
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Fabry Disease2335
Krabbe Disease2335
Sphingolipids metabolism pathway063

Research

Studies (204)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (5.88)18.2507
2000's72 (35.29)29.6817
2010's100 (49.02)24.3611
2020's20 (9.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.72 (24.57)
Research Supply Index5.33 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index52.00 (26.88)
Search Engine Supply Index2.70 (0.95)

This Compound (30.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews40 (19.42%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other166 (80.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]